China guideline for the screening and early detection of female breast cancer(2021, Beijing)
Breast cancer is the commonest malignant tumor among Chinese females, ranking first in terms of incidence of female cancers. Commissioned by the Disease Prevention and Control Bureau of National Health Commission of the People's Republic of China, the National Cancer Center formulated the Guideline for Screening and Early Diagnosis and Treatment of Female Breast Cancer in China according to WHO Handbook for Guideline Development. The methods on Cochrane China were referred to for the formulation of the system evaluation procedures. The GRADE methods for assessment, formulation and evaluation were adopted for the classification of evidence quality and recommendation strength, and the items were reported according to Reporting Items for Practice Guidelines in Healthcare. Based on the results of evaluation, the guideline gives evidence-based recommendations for the appropriate population and technical procedures for breast cancer screening and early diagnosis and treatment after comprehensive consideration of China's national conditions, the advantages and disadvantages of the evidence, the quality of the evidence, the economic cost of screening, the feedback of multidisciplinary clinical research respondents, and in-person expert consensus. It is aimed at regulating the practices of female breast cancer screening and early diagnosis and treatment and enhancing the effectiveness of the prevention and control of female breast cancer in China.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Zhonghua zhong liu za zhi [Chinese journal of oncology - 43(2021), 4 vom: 23. Apr., Seite 357-382 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
He, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast neoplasms |
|---|
| Anmerkungen: |
Date Completed 28.04.2021 Date Revised 28.04.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn112152-20210119-00061 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324556918 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324556918 | ||
| 003 | DE-627 | ||
| 005 | 20231225190554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn112152-20210119-00061 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1081.xml |
| 035 | |a (DE-627)NLM324556918 | ||
| 035 | |a (NLM)33902200 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a He, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a China guideline for the screening and early detection of female breast cancer(2021, Beijing) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2021 | ||
| 500 | |a Date Revised 28.04.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Breast cancer is the commonest malignant tumor among Chinese females, ranking first in terms of incidence of female cancers. Commissioned by the Disease Prevention and Control Bureau of National Health Commission of the People's Republic of China, the National Cancer Center formulated the Guideline for Screening and Early Diagnosis and Treatment of Female Breast Cancer in China according to WHO Handbook for Guideline Development. The methods on Cochrane China were referred to for the formulation of the system evaluation procedures. The GRADE methods for assessment, formulation and evaluation were adopted for the classification of evidence quality and recommendation strength, and the items were reported according to Reporting Items for Practice Guidelines in Healthcare. Based on the results of evaluation, the guideline gives evidence-based recommendations for the appropriate population and technical procedures for breast cancer screening and early diagnosis and treatment after comprehensive consideration of China's national conditions, the advantages and disadvantages of the evidence, the quality of the evidence, the economic cost of screening, the feedback of multidisciplinary clinical research respondents, and in-person expert consensus. It is aimed at regulating the practices of female breast cancer screening and early diagnosis and treatment and enhancing the effectiveness of the prevention and control of female breast cancer in China | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breast neoplasms | |
| 650 | 4 | |a China | |
| 650 | 4 | |a Early diagnosis and treatment | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Guideline | |
| 650 | 4 | |a Screening | |
| 700 | 1 | |a Chen, W Q |e verfasserin |4 aut | |
| 700 | 1 | |a Li, N |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, H B |e verfasserin |4 aut | |
| 700 | 1 | |a Li, J |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Li, J |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, J H |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, B S |e verfasserin |4 aut | |
| 700 | 0 | |a Consulting Group of China Guideline for the Screening and Early Diagnosis and Treatment of Female Breast Cancer |e verfasserin |4 aut | |
| 700 | 0 | |a Expert Group of China Guideline for the Screening and Early Diagnosis and Treatment of Female Breast Cancer |e verfasserin |4 aut | |
| 700 | 0 | |a Working Group of China Guideline for the Screening and Early Diagnosis and Treatment of Female Breast Cancer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua zhong liu za zhi [Chinese journal of oncology |d 1989 |g 43(2021), 4 vom: 23. Apr., Seite 357-382 |w (DE-627)NLM000961434 |x 0253-3766 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2021 |g number:4 |g day:23 |g month:04 |g pages:357-382 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn112152-20210119-00061 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2021 |e 4 |b 23 |c 04 |h 357-382 | ||